Recent Finacing
Recent Raise
Acticor Biotech is a clinical-stage company developing ACT017 (glenzocimab), a humanized Fab targeting platelet GPVI to inhibit thrombus growth while limiting bleeding risk, advancing Phase II stroke trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Acticor Biotech.
